Virtual Library

Start Your Search

A.A. Ansari



Author of

  • +

    P1.02 - Poster Session with Presenters Present (ID 454)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Biology/Pathology
    • Presentations: 1
    • +

      P1.02-038 - Over- Expression of Epidermal Growth Factor Receptor 1 (EGFR1) Gene in Serum of Adenocarcinoma Lung at a Tertiary Level Centre in North India (ID 5583)

      14:30 - 15:45  |  Author(s): A.A. Ansari

      • Abstract

      Background:
      Epidermal growth factor receptor (EGFR) is a cell surface protein that binds to epidermal growth factor. Over expression of EGFR1 in tumor tissue has been observed in upto 65% of advanced non small cell lung cancer, and has shown promising prognostic potential. In this study, we compared the EGFR1 gene expression in serum adenocarcinoma lung with healthy controls.

      Methods:
      We analyzed 61 newly diagnosed patients of adenocarcinoma lung and 50 healthy controls. RNA was isolated from blood serum of all subjects and real time PCR (RT- PCR) was performed after complementary DNA (cDNA) synthesis. The level of EGFR1 expression in serum was calculated by relative quantification method and expressed as fold-increase compared to compared with controls. Expression levels were also correlated with various clinico- pathological parameters.

      Results:
      Out of 61 patients, 42 were males. The mean (SD) age of the entire group was 54.5 (11.5) years. Most of the patients (79%) had stage IV disease. 23 (38%) patients were current/ ex- smokers, with median pack years of 10 (range, 0.5- 100). Majority of patients had KPS of 90 (51%) and ECOG 1 (74%) respectively. Activating mutations in EGFR were observed in the tissue of 14 (21.3%) of 61 patients; of these, 9 were exon- 19 deletions and 4 were exon- 21 point mutations. In the patients, a 19.66 mean- fold increase in serum EGFR gene expression was observed compared to healthy controls. No significant association was found between EGFR expression and other variables i.e., sex, age, smoking habit, performance status, stage of disease and EGFR mutation status.

      Conclusion:
      Serum EGFR1 gene was over expressed by >16 fold in advanced adenocarcinoma lung compared to healthy controls. The association of EGFR expression with other clinical disease characteristics needs further exploration.

  • +

    P2.01 - Poster Session with Presenters Present (ID 461)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Biology/Pathology
    • Presentations: 1
    • +

      P2.01-007 - Detection of Promoter DNA Methylation of APC, DAPK, and GSTP1 Genes in Tissue Biopsy and Matched Serum of Advanced Stage Lung Cancer Patients (ID 5595)

      14:30 - 15:45  |  Author(s): A.A. Ansari

      • Abstract

      Background:
      Promoter DNA hypermethylation is a well characterized epigenetic event and has been linked with early stages of lung carcinogenesis through inactivation of tumor suppressor genes. In this study, we studied the methylation status of APC, DAPK, and GSTP1 genes in tissue biopsy and serum of lung cancer patients and cancer-free controls.

      Methods:
      In this prospective study, 160 primary lung cancer patients and 70 cancer-free controls undergoing bronchoscopy for benign disease were recruited. DNA was isolated from tissue biopsy and serum of all the subjects and methylation-specific PCR of APC, DAPK, and GSTP1 was carried out after bisulfite conversion. Association of DNA methylation with various clinico-pathological parameters and survival was determined in lung cancer patients.

      Results:
      The methylation rates of APC, DAPK, and GSTP1 in tissue biopsy were 83.1%, 83.1%, and 78.1% for lung cancer patients and 72.9%, 70%, and 70% for cancer-free controls. The methylation rates of APC, DAPK, and GSTP1 in serum were 52.5%, 30.6%, and 65.6% for lung cancer patients and 14.3%, 18.6%, and 30% for cancer-free controls. In lung cancer patients, all three genes were methylated at significantly higher frequency in tissue biopsy than matched serum samples. No significant correlation was observed between methylation of any of three genes with clinico-pathological parameters, including survival.

      Conclusion:
      Present study did not demonstrating any evidence suggesting the role of promoter DNA methylation of APC, DAPK, and GSTP1 in lung carcinogenesis. However, follow-up of cancer-free controls, who were positive for DNA methylation, is required to confirm their role in early stages of lung carcinogenesis.